The privately-held Swiss company, 4-Antibody AG, has entered into a long-term collaboration with Boehringer Ingelheim to discover and develop antibodies against a number of undisclosed targets. The deal is valued at €177.5 million ---Subscribe to MedNous to access this article--- Company News
